Vaxcyte, Inc. financial data

Symbol
PCVX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
825 Industrial Road, Ste. 300, San Carlos, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
SutroVax, Inc. (to 4/3/2020)
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.44K % -21.7%
Debt-to-equity 6 % +2.04%
Return On Equity -23.5 % +7%
Return On Assets -22.2 % +7.11%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 125M shares +31%
Common Stock, Shares, Outstanding 124M shares +30.8%
Entity Public Float 4.1B USD +273%
Common Stock, Value, Issued 127K USD +29.6%
Weighted Average Number of Shares Outstanding, Basic 124M shares +21.7%
Weighted Average Number of Shares Outstanding, Diluted 124M shares +21.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 447M USD +59.8%
General and Administrative Expense 81.9M USD +48.5%
Operating Income (Loss) -604M USD -68.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -508M USD -69.5%
Earnings Per Share, Basic -4.61 USD/shares -38%
Earnings Per Share, Diluted -4.61 USD/shares -38%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.05B USD +92.6%
Other Assets, Current 3.44M USD +165%
Assets, Current 2.21B USD +70.9%
Property, Plant and Equipment, Net 163M USD +1328%
Operating Lease, Right-of-Use Asset 28.7M USD +75.7%
Other Assets, Noncurrent 60M USD +1781%
Assets 3.56B USD +138%
Accounts Payable, Current 18.2M USD +16%
Employee-related Liabilities, Current 12.2M USD +76.8%
Accrued Liabilities, Current 30.8M USD +105%
Liabilities, Current 124M USD +44.7%
Operating Lease, Liability, Noncurrent 18.3M USD +135%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 142M USD +52.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 139K USD
Retained Earnings (Accumulated Deficit) -1.25B USD -68.3%
Stockholders' Equity Attributable to Parent 3.42B USD +144%
Liabilities and Equity 3.56B USD +138%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -159M USD -234%
Net Cash Provided by (Used in) Financing Activities 818M USD +1869%
Net Cash Provided by (Used in) Investing Activities -451M USD -0.66%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 124M shares +30.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 214M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.05B USD +92.5%
Deferred Tax Assets, Valuation Allowance 288M USD +75.2%
Deferred Tax Assets, Gross 297M USD +74.2%
Operating Lease, Liability 28M USD +102%
Payments to Acquire Property, Plant, and Equipment 5.68M USD +1.23%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -505M USD -67.8%
Lessee, Operating Lease, Liability, to be Paid 34.4M USD +130%
Property, Plant and Equipment, Gross 177M USD +792%
Operating Lease, Liability, Current 9.64M USD +59.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.26M USD -37.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.5M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +13.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.46M USD +449%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.99M USD -57.5%
Deferred Tax Assets, Operating Loss Carryforwards 135M USD +21.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.45M USD +154%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.08M USD
Operating Lease, Payments 10.8M USD +64.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 999K USD +40.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%